The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: A 2-year trial

Bone

Volumn 46, Issue 3, 2010, Pages 655-659

  van Londen, G J ^a   Perera, S ^b   Vujevich, K T ^a   Sereika, S M ^b   Bhattacharya, R ^c   Greenspan, S L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CALCIUM CARBONATE PLUS VITAMIN D; EXEMESTANE; FULVESTRANT; LETROZOLE; MULTIVITAMIN; OSCAL PLUS D; PLACEBO; RISEDRONIC ACID; TAMOXIFEN CITRATE; TOREMIFENE; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ETIDRONIC ACID;

ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FEMUR SHAFT; HIP; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; FOLLOW UP; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHYSIOLOGY; POSTMENOPAUSE; RADIOGRAPHY;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE;

EID: 77649179859     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.10.019     Document Type: Article

References (22)

1. Brufsky A.M. Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors. Curr. Oncol. Rep. 2008, 10:18-26.
2. Reid D.M., Doughty J., Eastell R., Heys S.D., Howell A., McCloskey E.V., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat. Rev. 2008, 34(Suppl. 1):S3-18.
3. Coleman R.E., Body J.J., Gralow J.R., Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat. Rev. 2008, 34(Suppl 1):S31-42.
4. Hadji P., Body J.J., Aapro M.S., Brufsky A., Coleman R.E., Guise T., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol. 2008, 19:1407-1416.
5. Coleman R.E., Body J.J., Gralow J.R., Lipton A. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat. Rev. 2008, 34:S31-S42.
6. Chien A.J., Goss P.E. Aromatase inhibitors and bone health in women with breast cancer. J. Clin. Oncol. 2006, 24:5305-5312.
7. Seeman E., Delmas P.D. Bone quality-the material and structural basis of bone strength and fragility. N. Engl. J. Med. 2006, 354:2250-2261.
8. Greenspan S.L., Brufsky A., Lembersky B.C., Bhattacharya R., Vujevich K.T., Perera S., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J. Clin. Oncol. 2008, 26:2644-2652.
9. Beck T.J., Ruff C.B., Scott W.W., Plato C.C., Tobin J.D., Quan C.A. Sex differences in geometry of the femoral neck with aging: a structural analysis of bone mineral data. Calcif. Tissue Int. 1992, 50:24-29.
10. Beck T.J., Stone K.L., Oreskovic T.L., Hochberg M.C., Nevitt M.C., Genant H.K., Cummings S.R. Effects of current and discontinued estrogen replacement therapy on hip structural geometry: the study of osteoporotic fractures. J. Bone Miner. Res. 2001, 16:2103-2110.
11. Greenspan S.L., Beck T.J., Resnick N.M., Bhattacharya R., Parker R.A. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial. J. Bone Miner. Res. 2005, 20:1525-1532.
12. Dawson-Hughes B., Jacques P., Shipp C. Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am. J. Clin. Nutr. 1987, 46:685-687.
13. Beck T.J. Extending DXA beyond bone mineral density: understanding hip structure analysis. Curr. Osteoporos. Rep. 2007, 5:49-55.
14. Bonnick S.L. HSA: beyond BMD with DXA. Bone 2007, 41:S9-12.
15. Khoo B.C.C., Beck T.J., Qiao Q.H., Parakh P., Semanick L., Prince R.L., et al. In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multi-center clinical trials. Bone 2005, 37:112-121.
16. Kanis J.A. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos. Int. 1994, 4:368-381.
17. Uusi-Rasi K., Beck T.J., Semanick L.M., Daphtary M.M., Crans G.G., Desaiah D., et al. Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. Osteoporos. Int. 2006, 17:575-586.
18. Petit M.A., Beck T.J., Lin H.M., Bentley C., Legro R.S., Lloyd T. Femoral bone structural geometry adapts to mechanical loading and is influenced by sex steroids: the Penn State Young Women's Health Study. Bone 2004, 35:750-759.
19. Uusi-Rasi K., Semanick L.M., Zanchetta J.R., Bogado C.E., Eriksen E.F., Sato M., Beck T.J. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005, 36:948-958.
20. van Londen G.J., Perera S., Vujevich K.T., Sereika S.M., Bhattacharya R., Greenspan S.L. Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. Bone 2008, 43:274-278.
21. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999, 282:1344-1352. for the Vertebral Efficacy With Risedronate Therapy Study Group.
22. Beck T.J., Looker A.C., Ruff C.B., Sievanen H., Wahner H.W. Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J. Bone Miner. Res. 2000, 15:2297-2304.